Judith BalmaÃ±a

List of Publications by Year
in descending order

150 papers	10,028 citations	53660 45 h-index	39575 94 g-index

157 all docs	157 docs citations	157 times ranked	13814 citing authors

#	Article	IF	Citations
1	Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation. Journal of Clinical Oncology, 2015, 33, 244-250.	0.8	1,473
2	Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. New England Journal of Medicine, 2021, 384, 2394-2405.	13.9	764
3	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. Cancer Discovery, 2012, 2, 1048-1063.	7.7	384
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
6	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	0.6	280
7	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	0.8	270
8	Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic Oncology, 2016, 140, 199-203.	0.6	252
9	Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. PLoS Genetics, 2013, 9, e1003212.	1.5	244
10	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
11	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	2.9	215
12	A Phase Iâ€“II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. Clinical Cancer Research, 2017, 23, 4095-4106.	3.2	213
13	The BRCA1-Î”11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.4	208
14	The PREMM1,2,6 Model Predicts Risk of MLH1, MSH2, and MSH6 Germline Mutations Based on Cancer History. Gastroenterology, 2011, 140, 73-81.e5.	0.6	171
15	Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Research and Treatment, 2010, 121, 389-398.	1.1	170
16	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	3.3	169
17	Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome. JAMA - Journal of the American Medical Association, 2006, 296, 1469.	3.8	160
18	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152

#	Article	IF	Citations
19	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. Journal of Clinical Oncology, 2016, 34, 4071-4078.	0.8	147
20	Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 2012, 133, 1125-1130.	1.1	144
21	Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors. Annals of Oncology, 2014, 25, 1656-1663.	0.6	144
22	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	0.8	135
23	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	3.0	106
24	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of Clinical Investigation, 2016, 126, 2903-2918.	3.9	105
25	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. Human Mutation, 2019, 40, 1557-1578.	1.1	102
26	A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clinical Cancer Research, 2019, 25, 2717-2724.	3.2	102
27	FANCMc.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. Human Molecular Genetics, 2015, 24, 5345-5355.	1.4	91
28	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	5.8	90
29	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. Breast Cancer Research, 2016, 18, 15.	2.2	88
30	Role of POLE and POLD1 in familial cancer. Genetics in Medicine, 2020, 22, 2089-2100.	1.1	76
31	Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumors from patients with the Muir-Torre syndrome. Journal of Cutaneous Pathology, 2002, 29, 415-420.	0.7	72
32	Prevalence of germline MUTYH mutations among Lynch-like syndrome patients. European Journal of Cancer, 2014, 50, 2241-2250.	1.3	66
33	Phenotype Comparison of MLH1 and MSH2 Mutation Carriers in a Cohort of 1,914 Individuals Undergoing Clinical Genetic Testing in the United States. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 2044-2051.	1.1	65
34	Development and Validation of a Colon Cancer Risk Assessment Tool for Patients Undergoing Colonoscopy. American Journal of Gastroenterology, 2009, 104, 1508-1518.	0.2	62
35	Opinion about reproductive decision making among individuals undergoing BRCA1/2 genetic testing in a multicentre Spanish cohort. Human Reproduction, 2008, 24, 1000-1006.	0.4	61
36	Screening and surveillance in hereditary gastrointestinal cancers: Recommendations from the European Society of Digestive Oncology (ESDO)Âexpert discussion at the 20th European Society for Medical Oncology (ESMO)/World Congress on Gastrointestinal Cancer, Barcelona, June 2018. European Journal of Cancer, 2018, 104, 91-103.	1.3	60

#	Article	IF	Citations
37	Validation and Extension of the PREMM1,2 Model in a Population-Based Cohort of Colorectal Cancer Patients. Gastroenterology, 2008, 134, 39-46.	0.6	57
38	Prevalence and Characteristics of MUTYH-Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps. Clinical Cancer Research, 2014, 20, 1158-1168.	3.2	57
39	Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research and Treatment, 2010, 119, 221-232.	1.1	56
40	Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. Breast Cancer Research and Treatment, 2012, 132, 1009-1023.	1.1	56
41	Computational Tools for Splicing Defect Prediction in Breast/Ovarian Cancer Genes: How Efficient Are They at Predicting RNA Alterations?. Frontiers in Genetics, 2018, 9, 366.	1.1	53
42	Multigene panel testing beyond BRCA1/2 in breast/ovarian cancer Spanish families and clinical actionability of findings. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2495-2513.	1.2	53
43	Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer. Breast Cancer Research and Treatment, 2012, 132, 307-315.	1.1	50
44	Comparison of the clinical prediction model PREMM_{1,2,6}and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut, 2013, 62, 272-279.	6.1	49
45	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	2.0	47
46	Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review. Advances in Therapy, 2016, 33, 129-150.	1.3	46
47	Attitudes Toward Prenatal Genetic Testing in Patients With Familial Adenomatous Polyposis. American Journal of Gastroenterology, 2007, 102, 1284-1290.	0.2	45
48	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	1.1	45
49	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature Communications, 2019, 10, 5661.	5.8	45
50	Analysis of PALB2 Gene in BRCA1/BRCA2 Negative Spanish Hereditary Breast/Ovarian Cancer Families with Pancreatic Cancer Cases. PLoS ONE, 2013, 8, e67538.	1.1	44
51	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. Nature Cancer, 2022, 3, 251-261.	5.7	44
52	Stumbling Blocks on the Path to Personalized Medicine in Breast Cancer: The Case of PARP Inhibitors for BRCA1/2-Associated Cancers. Cancer Discovery, 2011, 1, 29-34.	7.7	43
53	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	0.8	43
54	Genetic counseling program in familial breast cancer: Analysis of its effectiveness, cost and cost-effectiveness ratio. International Journal of Cancer, 2004, 112, 647-652.	2.3	41

#	Article	IF	Citations
55	Performance of PREMM1,2,6, MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genetics in Medicine, 2012, 14, 670-680.	1.1	40
56	POLEandPOLD1screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget, 2017, 8, 26732-26743.	0.8	40
57	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.4	40
58	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
59	Identification of genetic test results with conflicting interpretations in prospective registry of multiplex testing (PROMPT).. Journal of Clinical Oncology, 2016, 34, 1510-1510.	0.8	38
60	Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment, 2014, 147, 185-191.	1.1	37
61	Factors Associated with Enrollment in Cancer Genetics Research. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1355-1359.	1.1	36
62	What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure?. Breast, 2012, 21, 755-760.	0.9	36
63	Clinical Subtypes and Molecular Characteristics of Serrated Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 705-711.	2.4	36
64	SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer. Breast Cancer Research and Treatment, 2015, 154, 351-357.	1.1	35
65	Management of individuals with germline variants in PALB2: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2021, 23, 1416-1423.	1.1	34
66	RNA analysis of eightBRCA1andBRCA2unclassified variants identified in breast/ovarian cancer families from Spain. Human Mutation, 2003, 22, 337-337.	1.1	33
67	Uptake of predictive testing among relatives of BRCA1 and BRCA2 families: a multicenter study in northeastern Spain. Familial Cancer, 2010, 9, 297-304.	0.9	32
68	Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. International Journal of Cancer, 2019, 145, 2682-2691.	2.3	30
69	MLH1 Founder Mutations with Moderate Penetrance in Spanish Lynch Syndrome Families. Cancer Research, 2010, 70, 7379-7391.	0.4	29
70	RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families. Breast Cancer Research and Treatment, 2014, 147, 133-143.	1.1	29
71	Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. Journal of the National Cancer Institute, 2016, 108, .	3.0	29
72	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology, 2017, 153, 106-112.e2.	0.6	28

#	Article	IF	Citations
73	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
74	International distribution and age estimation of the Portuguese BRCA2 c.156_157insAlu founder mutation. Breast Cancer Research and Treatment, 2011, 127, 671-679.	1.1	27
75	BRCA1andBRCA2pathogenic sequence variants in women of African origin or ancestry. Human Mutation, 2019, 40, 1781-1796.	1.1	26
76	Screening of BRCA1/2 deep intronic regions by targeted gene sequencing identifies the first germline BRCA1 variant causing pseudoexon activation in a patient with breast/ovarian cancer. Journal of Medical Genetics, 2019, 56, 63-74.	1.5	26
77	Germline mutations in NF1 and BRCA1 in a family with neurofibromatosis type 1 and early-onset breast cancer. Breast Cancer Research and Treatment, 2013, 139, 597-602.	1.1	25
78	Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancerâ€"an European consensus statement and expert recommendations. European Journal of Cancer, 2019, 106, 54-60.	1.3	25
79	Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5â€"13/TESARO PR-30â€"50â€"10-C BRAVO Study. Clinical Cancer Research, 2021, 27, 5482-5491.	3.2	25
80	About 1% of the breast and ovarian Spanish families testing negative for BRCA1 and BRCA2 are carriers of RAD51D pathogenic variants. International Journal of Cancer, 2014, 134, 2088-2097.	2.3	24
81	Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for genetic testing. Familial Cancer, 2010, 9, 187-191.	0.9	23
82	Challenges to the Development of New Agents for Molecularly Defined Patient Subsets: Lessons From BRCA1/2-Associated Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4224-4226.	0.8	23
83	Mammographic density and breast cancer in women from high risk families. Breast Cancer Research, 2015, 17, 93.	2.2	22
84	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. European Journal of Medical Genetics, 2021, 64, 104350.	0.7	22
85	Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. International Journal of Gynecological Cancer, 2019, 29, 1396-1404.	1.2	19
86	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
87	Haplotype analysis of theBRCA29254delATCAT recurrent mutation in breast/ovarian cancer families from Spain. Human Mutation, 2003, 21, 452-452.	1.1	18
88	Comprehensive genetic and endoscopic evaluation may be necessary to distinguish sporadic versus familial adenomatous polyposisâ€"associated abdominal desmoid tumors. Surgery, 2004, 135, 683-689.	1.0	18
89	Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics. Clinical and Translational Oncology, 2016, 18, 981-987.	1.2	18
90	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	1.5	18

#	Article	IF	Citations
91	Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.4	17
92	Role of Splicing Regulatory Elements and In Silico Tools Usage in the Identification of Deep Intronic Splicing Variants in Hereditary Breast/Ovarian Cancer Genes. Cancers, 2021, 13, 3341.	1.7	17
93	Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study.. Journal of Clinical Oncology, 2013, 31, 11024-11024.	0.8	17
94	Prediction models in Lynch syndrome. Familial Cancer, 2013, 12, 217-228.	0.9	16
95	Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 110, 914-917.	3.0	16
96	Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction. European Journal of Cancer, 2020, 132, 53-60.	1.3	16
97	Caution Should Be Used When Interpreting Alterations Affecting the Exon 3 of the BRCA2 Gene in Breast/Ovarian Cancer Families. Journal of Clinical Oncology, 2007, 25, 5035-5036.	0.8	15
98	Analysis of Lynch Syndrome Mismatch Repair Genes in Women with Endometrial Cancer. Oncology, 2016, 91, 171-176.	0.9	15
99	European Breast Cancer Council manifesto 2018: GeneticÂrisk prediction testing in breast cancer. European Journal of Cancer, 2019, 106, 45-53.	1.3	15
100	Comprehensive Constitutional Genetic and Epigenetic Characterization of Lynch-Like Individuals. Cancers, 2020, 12, 1799.	1.7	15
101	Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. European Journal of Cancer, 2018, 104, 160-168.	1.3	14
102	Chromosome fragility in the buccal epithelium in patients with Fanconi anemia. Cancer Letters, 2020, 472, 1-7.	3.2	14
103	Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin. Breast Cancer Research and Treatment, 2012, 133, 273-283.	1.1	13
104	Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants. Npj Breast Cancer, 2021, 7, 16.	2.3	13
105	Evidence for a link between TNFRSF11A and risk of breast cancer. Breast Cancer Research and Treatment, 2011, 129, 947-954.	1.1	12
106	A phase II open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation.. Journal of Clinical Oncology, 2015, 33, 5513-5513.	0.8	12
107	Incorporation of semiâ€quantitative analysis of splicing alterations for the clinical interpretation of variants inBRCA1andBRCA2genes. Human Mutation, 2019, 40, 2296-2317.	1.1	11
108	BARD1 Pathogenic Variants Are Associated with Triple-Negative Breast Cancer in a Spanish Hereditary Breast and Ovarian Cancer Cohort. Genes, 2021, 12, 150.	1.0	11

#	Article	IF	Citations
109	Data reduction for prediction: A case study on robust coding of age and family history for the risk of having a genetic mutation. Statistics in Medicine, 2007, 26, 5545-5556.	0.8	10
110	Detection of the CHEK2 1100delC mutation by MLPA BRCA1/2 analysis: a worthwhile strategy for its clinical applicability in 1100delC low-frequency populations?. Breast Cancer Research and Treatment, 2008, 107, 455-457.	1.1	10
111	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precision Oncology, 2020, 4, 505-513.	1.5	10
112	Paired Somatic-Germline Testing of 15 Polyposis and Colorectal Cancerâ€“Predisposing Genes Highlights the Role of APC Mosaicism in de Novo Familial Adenomatous Polyposis. Journal of Molecular Diagnostics, 2021, 23, 1452-1459.	1.2	10
113	A novel de novo BRCA2 mutation of paternal origin identified in a Spanish woman with early onset bilateral breast cancer. Breast Cancer Research and Treatment, 2010, 121, 221-225.	1.1	9
114	Novel BRCA1 deleterious mutation (c.1949_1950delTA) in a woman of Senegalese descent with triple-negative early-onset breast cancer. Oncology Letters, 2011, 2, 1287-1289.	0.8	9
115	The variants BRCA1 IVS6-1G>A and BRCA2 IVS15+1G>A lead to aberrant splicing of the transcripts. Breast Cancer Research and Treatment, 2009, 117, 461-465.	1.1	8
116	A phase III randomized trial of niraparib versus physicianâ€™s choice in previously treated, HER2-negative, germline-BRCA mutated breast cancer patients: Intergroup study EORTC-1307-BCG and BIG5-13.. Journal of Clinical Oncology, 2014, 32, TPS659-TPS659.	0.8	7
117	Germline ATM mutational analysis in BRCA1/BRCA2 negative hereditary breast cancer families by MALDI-TOF mass spectrometry. Breast Cancer Research and Treatment, 2011, 128, 573-579.	1.1	6
118	Mutation analysis of the SHFM1 gene in breast/ovarian cancer families. Journal of Cancer Research and Clinical Oncology, 2013, 139, 529-532.	1.2	6
119	Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T. Breast Cancer Research and Treatment, 2019, 174, 543-550.	1.1	6
120	Phase I, open-label study of olaparib plus cisplatin in patients with advanced solid tumors.. Journal of Clinical Oncology, 2012, 30, 1009-1009.	0.8	6
121	BRIP1as an ovarian cancer susceptibility gene: ready for the clinic?. Journal of the National Cancer Institute, 2015, 107, djv262.	3.0	5
122	SOLTI NeoPARP: A phase II, randomized study of two schedules of iniparib plus paclitaxel and paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2012, 30, 1011-1011.	0.8	5
123	Sex Ratio Distortion in Offspring of Families with BRCA1 or BRCA2 Mutant Alleles: An Ascertainment Bias Phenomenon?. Breast Cancer Research and Treatment, 2005, 92, 273-277.	1.1	4
124	Mutation analysis of the BCCIP gene for breast cancer susceptibility in breast/ovarian cancer families. Gynecologic Oncology, 2013, 131, 460-463.	0.6	4
125	BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast/ovarian cancer patients. Cancer Genetics, 2021, 258-259, 10-17.	0.2	4
126	Clinical consequences of BRCA2 hypomorphism. Npj Breast Cancer, 2021, 7, 117.	2.3	3

#	Article	IF	Citations
127	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 509-509.	0.8	3
128	Prospective registry of multiplex testing (PROMPT): A web-based platform to assess cancer risk of genetic variants.. Journal of Clinical Oncology, 2016, 34, 1518-1518.	0.8	3
129	Prospective Registry of Multiplex Testing (PROMPT): Feasible and sustainable.. Journal of Clinical Oncology, 2018, 36, 1543-1543.	0.8	3
130	Screening for Lynch Syndrome among Patients with Newly Diagnosed Endometrial Cancer: A Comprehensive Review. Tumori, 2016, 102, P1-7P.	0.6	2
131	Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analysis of the global BREAKOUT study. Breast Cancer, 2022, 29, 92-102.	1.3	2
132	A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).. Journal of Clinical Oncology, 2015, 33, TPS1108-TPS1108.	0.8	2
133	Efficacy and safety of olaparib monotherapy in a subgroup of patients with a germline BRCA1/2 mutation and advanced ovarian cancer from a Phase II open-label study.. Journal of Clinical Oncology, 2015, 33, 5529-5529.	0.8	2
134	Abstract OT2-24-02: ZEST: Randomized phase III study evaluating efficacy and safety of niraparib in patients with HER2-negative BRCA-mutated or triple-negative breast cancer with detectable circulating tumor DNA after definitive therapy. Cancer Research, 2022, 82, OT2-24-02-OT2-24-02.	0.4	2
135	Current Systemic Treatments for the Hereditary Cancer Syndromes: Drug Development in Light of Genomic Defects. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 808-824.	1.8	2
136	The Role of Platinum Compounds for the Treatment of Breast Cancer. Current Breast Cancer Reports, 2013, 5, 11-22.	0.5	1
137	A 10-year step forward in hereditary cancer in Spain. Clinical and Translational Oncology, 2013, 15, 1-2.	1.2	1
138	PARP inhibitors in ovarian cancer. British Journal of Cancer, 2015, 113, S1-S2.	2.9	1
139	Reply to R.L. Nussbaum et al and J.S. Dolinsky et al. Journal of Clinical Oncology, 2017, 35, 1262-1263.	0.8	1
140	Patientsâ€™ and professionalsâ€™ perspective of non-in-person visits in hereditary cancer: predictors and impact of the COVID-19 pandemic. Genetics in Medicine, 2021, 23, 1450-1457.	1.1	1
141	Prospective Registry of Multiplex Testing (PROMPT): Follow-up.. Journal of Clinical Oncology, 2019, 37, 1527-1527.	0.8	1
142	What is the hereditary non-polyposis colorectal cancer syndrome?. , 2000, 2, 191-201.		1
143	BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer, 2006, 106, 2528-2529.	2.0	0
144	Surveillance Guidelines for Hereditary Colorectal Cancer Syndromes. , 2018, , 305-326.		0

#	Article	IF	Citations
145	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. Journal of Clinical Oncology, 2012, 30, 619-619.	0.8	0
146	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 566-566.	0.8	0
147	Preliminary analysis of risk factors associated with peritoneal carcinomatosis (PC) after prophylactic bilateral salpingoophorectomy (PBSO) in patients with a BRCA mutation.. Journal of Clinical Oncology, 2013, 31, 1509-1509.	0.8	0
148	New contributions in the process of breast cancer patient participation in clinical trials in Spain: A qualitative multicenter study.. Journal of Clinical Oncology, 2015, 33, e20570-e20570.	0.8	0
149	Multiplex testing in high risk BRCA1/2-negative families.. Journal of Clinical Oncology, 2015, 33, e12557-e12557.	0.8	0
150	Abstract PD5-06: Safety of assisted reproductive technologies (ART) following treatment completion in young women with germline BRCA pathogenic variants having a pregnancy after breast cancer. Cancer Research, 2022, 82, PD5-06-PD5-06.	0.4	0